Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship
Shapiro, Irina M, Kolev, Vihren N, Vidal, Christian M, Kadariya, Yuwaraj, Ring, Jennifer E, Wright, Quentin, Weaver, David T, Menges, Craig, Padval, Mahesh, McClatchey, Andrea I, Xu, Qunli, Testa, Joseph R, Pachter, Jonathan A
Published in Science translational medicine (21.05.2014)
Published in Science translational medicine (21.05.2014)
Get more information
Journal Article
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells
Kolev, Vihren N, Wright, Quentin G, Vidal, Christian M, Ring, Jennifer E, Shapiro, Irina M, Ricono, Jill, Weaver, David T, Padval, Mahesh V, Pachter, Jonathan A, Xu, Qunli
Published in Cancer research (Chicago, Ill.) (15.01.2015)
Published in Cancer research (Chicago, Ill.) (15.01.2015)
Get full text
Journal Article
Inhibition of FAK kinase activity preferentially targets cancer stem cells
Kolev, Vihren N, Tam, Winnie F, Wright, Quentin G, McDermott, Sean P, Vidal, Christian M, Shapiro, Irina M, Xu, Qunli, Wicha, Max S, Pachter, Jonathan A, Weaver, David T
Published in Oncotarget (01.08.2017)
Published in Oncotarget (01.08.2017)
Get full text
Journal Article
Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target cancer stem cells
Xu, Qunli, Kolev, Vihren N, Wright, Quentin G, Shapiro, Irina M, Vidal, Christian M., Padval, Mahesh, Keegan, Mitchell, Paterson, Daniel, Horobin, Joanna, Pachter, Jonathan A
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Abstract 4797: VS-6063 (defactinib) targets cancer stem cells directly and through inhibition of tumor-associated macrophages and cytokine production
Pachter, Jonathan A., Ring, Jennifer E., Kolev, Vihren N., Shapiro, Irina M., Vidal, Christian M., Padval, Mahesh V., Xu, Qunli
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Abstract B13: Predictive biomarkers for FAK inhibitor sensitivity in ovarian cancer
Shapiro, Irina M., Vidal, Christian M., Kolev, Vihren N., Weaver, David T., Pachter, Jonathan A.
Published in Clinical cancer research (01.10.2013)
Published in Clinical cancer research (01.10.2013)
Get full text
Journal Article
Abstract A39: FAK inhibitors VS-6063 and VS-4718 preferentially target ovarian cancer stem cells
Kolev, Vihren N., Wright, Quentin G., Vidal, Christian M., Tam, Winnie F., Pavdal, Mahesh V., Xu, Qunli, Pachter, Jonathan A.
Published in Clinical cancer research (01.10.2013)
Published in Clinical cancer research (01.10.2013)
Get full text
Journal Article
Abstract 3908: Focal adhesion kinase (FAK) inhibitor VS-6063 (defactinib) preferentially targets cancer stem cells in triple negative breast cancer
Xu, Qunli, Kolev, Vihren N., Wright, Quentin G., Ring, Jennifer E., Vidal, Christian M., Shapiro, Irina M., Weaver, David T., Padval, Mahesh V., Pachter, Jonathan A.
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Abstract 3906: Combined inhibition of PI3K isoforms and mTOR kinase is critical for cancer stem cell inhibition by VS-5584
Kolev, Vihren N., Wright, Quentin G., Weaver, David T., Ring, Jennifer E., Vidal, Christian M., Pavdal, Mahesh V., Pachter, Jonathan A., Xu, Qunli
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article
Sensitivity of malignant mesothelioma lacking Merlin to the FAK inhibitor VS-6063: Evaluation of merlin/NF2 status in clinical samples
Pachter, Jonathan A., Shapiro, Irina M, Weaver, David T., Vidal, Christian M., Ring, Jennifer E., Keegan, Mitchell, Xu, Qunli, Menges, Craig, Testa, Joseph R., Paterson, Daniel
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells
Vidal, Christian M., Kolev, Vihren N., Wright, Quentin G., Tam, Winnie F., Weaver, David T., Padval, Mahesh V., Xu, Qunli, Pachter, Jonathan A.
Published in Molecular cancer therapeutics (01.11.2013)
Published in Molecular cancer therapeutics (01.11.2013)
Get full text
Journal Article
Abstract C262: Malignant mesothelioma lacking merlin shows enhanced sensitivity to the FAK inhibitor defactinib (VS-6063): Elucidation of the merlin-FAK relationship
Shapiro, Irina M., Kolev, Vihren N., Kadariya, Yuwaraj, Vidal, Christian M., Wright, Quentin G., Ring, Jennifer E., Menges, Craig, Testa, Joseph R., Xu, Qunli, Pachter, Jonathan A.
Published in Molecular cancer therapeutics (01.11.2013)
Published in Molecular cancer therapeutics (01.11.2013)
Get full text
Journal Article
Abstract B52: Dual mTORC1/2 and PI3K inhibitor VS-5584 preferentially targets cancer stem cells
Kolev, Vihren N., Wright, Quentin G., Vidal, Christian M., Ring, Jennifer E., Shapiro, Irina M., Weaver, David T., Pavdal, Mahesh V., Pachter, Jonathan A., Xu, Qunli
Published in Molecular cancer therapeutics (01.11.2013)
Published in Molecular cancer therapeutics (01.11.2013)
Get full text
Journal Article
Abstract 924: FAK inhibition preferentially attenuates growth of Merlin-negative malignant mesotheliomas: role of cancer stem cells
Shapiro, Irina M., Kolev, Vihren N., Vidal, Christian M., Ring, Jennifer E., Keegan, Mitchell, Xu, Qunli, Menges, Craig W., Testa, Joseph R., Pachter, Jonathan A.
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article